Iris Kliers

693 total citations · 2 hit papers
15 papers, 317 citations indexed

About

Iris Kliers is a scholar working on Epidemiology, Molecular Biology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Iris Kliers has authored 15 papers receiving a total of 317 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Epidemiology, 6 papers in Molecular Biology and 5 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Iris Kliers's work include Liver Disease Diagnosis and Treatment (8 papers), Metabolism, Diabetes, and Cancer (6 papers) and Diabetes Treatment and Management (5 papers). Iris Kliers is often cited by papers focused on Liver Disease Diagnosis and Treatment (8 papers), Metabolism, Diabetes, and Cancer (6 papers) and Diabetes Treatment and Management (5 papers). Iris Kliers collaborates with scholars based in Israel, United Kingdom and Denmark. Iris Kliers's co-authors include Philip N. Newsome, Michael Roden, Mary E. Rinella, Elisabetta Bugianesi, Vlad Ratziu, Michelle T. Long, Mette Skalshøi Kjær, Gad Segal, Arun J. Sanyal and Kristiane A. Engebretsen and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and Ophthalmology.

In The Last Decade

Iris Kliers

12 papers receiving 304 citations

Hit Papers

Phase 3 Trial of Semaglutide in Metabolic D... 2024 2026 2025 2025 2024 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
    2025 170 citations Philip N. Newsome, Iris Kliers et al. New England Journal of Medicine profile →
  2. Semaglutide 2.4 mg in Participants With Metabolic Dysfunction‐Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial
    2024 63 citations Philip N. Newsome, Arun J. Sanyal et al. Alimentary Pharmacology & Therapeutics profile →

Peers

Iris Kliers
Yuka Hayakawa Japan
Catarina Vale Portugal
Eugènia Mariné Barjoan France
Zhengyi Wang Australia
Yoshinori Kakutani Japan
Maria Rosa Barcellona Italy
Aika Miya Japan
Sylwia Szymańska Poland
Charlotte Wilhelmina Wernberg Denmark
Yunyi Le China
Yuka Hayakawa Japan
Iris Kliers
Citations per year, relative to Iris Kliers Iris Kliers (= 1×) peers Yuka Hayakawa

Countries citing papers authored by Iris Kliers

Since Specialization
Citations

This map shows the geographic impact of Iris Kliers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Iris Kliers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Iris Kliers more than expected).

Fields of papers citing papers by Iris Kliers

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Iris Kliers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Iris Kliers. The network helps show where Iris Kliers may publish in the future.

Co-authorship network of co-authors of Iris Kliers

This figure shows the co-authorship network connecting the top 25 collaborators of Iris Kliers. A scholar is included among the top collaborators of Iris Kliers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Iris Kliers. Iris Kliers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Newsome, Philip N., Iris Kliers, Michelle T. Long, et al.. (2025). Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis. New England Journal of Medicine. 392(21). 2089–2099. 170 indexed citations breakdown →
2.
Schattenberg, Jörn M., Henning Grønbæk, Iris Kliers, et al.. (2025). Proteomic signatures reflect effects of semaglutide treatment for MASH. JHEP Reports. 7(10). 101521–101521.
3.
Meyhöfer, Sebastian M., Bertrand Cariou, Cíntia Cercato, et al.. (2024). Semaglutide improves cardiovascular outcomes in patients with high risk for metabolic dysfunction-associated steatohepatitis – a subgroup analysis from the SELECT trial. Obesity Research & Clinical Practice. 18(5). S9–S9. 2 indexed citations
4.
Newsome, Philip N., Arun J. Sanyal, Kristiane A. Engebretsen, et al.. (2024). Semaglutide 2.4 mg in Participants With Metabolic Dysfunction‐Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial. Alimentary Pharmacology & Therapeutics. 60(11-12). 1525–1533. 63 indexed citations breakdown →
5.
Tsoukas, Michael A., Sebastian M. Meyhöfer, Bertrand Cariou, et al.. (2024). Semaglutide Improves Cardiovascular Outcomes in Patients With High Risk for Metabolic Dysfunction-associated Steatohepatitis – A Subgroup Analysis From the SELECT Trial. Canadian Journal of Diabetes. 48(7). S35–S36. 2 indexed citations
6.
7.
8.
9.
Goren, Idan, Ariel Israel, Narin N. Carmel Neiderman, et al.. (2016). Vomiting and Hyponatremia Are Risk Factors for Worse Clinical Outcomes Among Patients Hospitalized Due to Nonsurgical Abdominal Pain. Medicine. 95(14). e3274–e3274.
10.
Dagan, Amir, et al.. (2016). Disability Progression in Multiple Sclerosis Is Affected by the Emergence of Comorbid Arterial Hypertension. Journal of Clinical Neurology. 12(3). 345–345. 19 indexed citations
11.
Kliers, Iris, et al.. (2016). Listeria Peritonitis in a Patient Treated with Peritoneal Dialysis.. PubMed. 18(2). 129–30. 7 indexed citations
12.
Hassin‐Baer, Sharon, et al.. (2015). Low Norton Scale Score Predicts Worse Outcomes for Parkinson’s Disease Patients Hospitalized Due to Infection. SHILAP Revista de lepidopterología. 1. 3690686283–3690686283. 3 indexed citations
13.
Leshem, Eyal, Iris Kliers, Mati Bakon, et al.. (2011). Neurocysticercosis in Travelers: A Nation‐Wide Study in Israel. Journal of Travel Medicine. 18(3). 191–197. 20 indexed citations
14.
Leshem, Eyal, et al.. (2010). [Neurocysticercosis in Israel].. PubMed. 149(9). 576–9, 620. 2 indexed citations
15.
Kaiserman, Igor, Irene Anteby, Itay Chowers, et al.. (2002). Changes in ultrasound findings in posterior uveal melanoma after ruthenium 106 brachytherapy. Ophthalmology. 109(6). 1137–1141. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yuka Hayakawa Breakdown of academic impact, for papers by Catarina Vale Breakdown of academic impact, for papers by Eugènia Mariné Barjoan Breakdown of academic impact, for papers by Zhengyi Wang Breakdown of academic impact, for papers by Yoshinori Kakutani Breakdown of academic impact, for papers by Maria Rosa Barcellona Breakdown of academic impact, for papers by Aika Miya Breakdown of academic impact, for papers by Sylwia Szymańska Breakdown of academic impact, for papers by Charlotte Wilhelmina Wernberg Breakdown of academic impact, for papers by Yunyi Le
Rankless by CCL
2026